BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16049296)

  • 1. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.
    Tanaka K; Honna T; Kitano Y; Kuroda T; Tanaka K; Morikawa N; Matsuda H; Kawashima N; Matsuoka K; Miyauchi J
    J Clin Pathol; 2005 Aug; 58(8):884-7. PubMed ID: 16049296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
    Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
    Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.
    Tanaka S; Hirohashi K; Uenishi T; Yamamoto T; Hamba H; Kubo S; Tanaka H; Shuto T; Ogawa M; Kinoshita H
    Hepatogastroenterology; 2004; 51(57):839-41. PubMed ID: 15143930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin.
    Asayama Y; Taguchi Ki K; Aishima Si S; Nishi H; Masuda K; Tsuneyoshi M
    Liver; 2002 Feb; 22(1):43-50. PubMed ID: 11906618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary liver cancer with dual expression of hepatocyte and bile duct epithelial markers.
    Uenishi T; Hirohashi K; Shuto T; Tsukamoto T; Yamamoto T; Ogawa M; Kubo S; Tanaka H; Kinoshita H
    Hepatogastroenterology; 2002; 49(46):1092-4. PubMed ID: 12143210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepato-cholangiocarcinoma with diffuse metastases and hypercalcemia].
    Pérez Roldán F; Carretero L; Aguirre A; Bañares R; Casado M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1995 Oct; 87(10):743-7. PubMed ID: 8519543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
    Lee JH; Chung GE; Yu SJ; Hwang SY; Kim JS; Kim HY; Yoon JH; Lee HS; Yi NJ; Suh KS; Lee KU; Jang JJ; Kim YJ
    J Clin Gastroenterol; 2011 Jan; 45(1):69-75. PubMed ID: 20142755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
    Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
    Hunt JP; Varnholt H
    Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.
    Lin G; Toh CH; Wu RC; Ko SF; Ng SH; Chou WC; Tseng JH
    Int J Clin Pract; 2008 Aug; 62(8):1199-205. PubMed ID: 17537192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.
    Ng IO; Shek TW; Nicholls J; Ma LT
    J Gastroenterol Hepatol; 1998 Jan; 13(1):34-40. PubMed ID: 9737569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synchronous double cancers of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a case report and review of the literature.
    Wu C; Bai DS; Jiang GQ; Jin SJ
    World J Surg Oncol; 2014 Nov; 12():337. PubMed ID: 25385169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.